Entera Bio (5DT) Financial Statements
Entera Bio Financial Overview
Entera Bio's market cap is currently $498.34M. The company's EPS TTM is $-0.35; its P/E ratio is -9.23; Entera Bio is estimated to report earnings on November 5, 2026, and the estimated EPS forecast is $-0.06. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Mar 23 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 42.00K | $ 181.00K | $ 0.00 | $ 134.00K | $ 571.00K |
| Gross Profit | $ 0.00 | $ 9.00K | $ -56.00K | $ -31.00K | $ 198.00K |
| Operating Income | $ -11.53M | $ -9.59M | $ -8.94M | $ -13.07M | $ -12.22M |
| EBITDA | $ -11.41M | $ -9.48M | $ -8.80M | $ -12.87M | $ -12.16M |
| Net Income | $ -11.44M | $ -9.54M | $ -8.89M | $ -13.07M | $ -12.19M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 7.11M | $ 8.66M | $ 11.02M | $ 12.31M | $ 24.89M |
| Total Assets | $ 15.99M | $ 9.39M | $ 11.77M | $ 13.13M | $ 25.99M |
| Total Debt | $ 490.00K | $ 272.00K | $ 390.00K | $ 91.00K | $ 302.00K |
| Net Debt | $ -6.62M | $ -8.39M | $ -10.63M | $ -12.22M | $ -24.59M |
| Total Liabilities | $ 2.89M | $ 1.31M | $ 1.38M | $ 1.37M | $ 3.42M |
| Stockholders' Equity | $ 13.10M | $ 8.08M | $ 10.39M | $ 11.75M | $ 22.57M |
| Cash Flow | |||||
| Free Cash Flow | $ -7.48M | $ -6.82M | $ -7.33M | $ -12.55M | $ -9.08M |
| Operating Cash Flow | $ -7.37M | $ -6.82M | $ -7.31M | $ -12.50M | $ -9.06M |
| Investing Cash Flow | $ -107.00K | $ -3.00K | $ -17.00K | $ -102.00K | $ -17.00K |
| Financing Cash Flow | $ 13.71M | $ 4.48M | $ 6.04M | $ 13.00K | $ 25.38M |
Currency in USD
